Johnson & Johnson $JNJ Stock Position Increased by Sax Wealth Advisors LLC

Key Points

• Sax Wealth Advisors increased its Johnson & Johnson position by 11.7% in the third quarter, bringing its holdings to 40,886 shares valued at approximately $10.8 million. Institutional investors collectively own 69.55% of J&J.
• J&J’s third-quarter adjusted earnings and revenue exceeded expectations, and the company raised its 2026 adjusted EPS outlook to approximately $11.05–$11.15. However, reported EPS declined from the prior year, while MedTech weakness and a potential hips-and-knees spinoff remain concerns.
• JNJ shares fell 6.7% to $246.09, despite the company maintaining its $1.34 quarterly dividend and receiving a “Moderate Buy” consensus rating with an average analyst price target of $276.22.

Sax Wealth Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 40,886 shares of the company's stock after purchasing an additional 4,277 shares during the quarter. Sax Wealth Advisors LLC's holdings in Johnson & Johnson were worth $10,824,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Fermata Advisors LLC lifted its position in shares of Johnson & Johnson by 2.5% during the 3rd quarter. Fermata Advisors LLC now owns 5,522 shares of the company's stock worth $1,462,000 after buying an additional 134 shares during the last quarter. NorthCrest Asset Manangement LLC lifted its holdings in Johnson & Johnson by 6.5% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 173,177 shares of the company's stock worth $44,416,000 after buying an additional 10,574 shares during the period. Vertrix Wealth Management LLC raised its holdings in Johnson & Johnson by 1.5% during the 3rd quarter. Vertrix Wealth Management LLC now owns 14,714 shares of the company's stock worth $3,895,000 after purchasing an additional 222 shares during the last quarter. Sacks & Associates LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter worth about $279,000. Finally, Roan Capital Partners boosted its holdings in shares of Johnson & Johnson by 49.1% during the 3rd quarter. Roan Capital Partners now owns 1,281 shares of the company's stock worth $339,000 after buying an additional 422 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted earnings per share were $2.59 versus the $2.53 consensus, while revenue rose 5.9% year over year to $25.40 billion, slightly above estimates. Growth in Innovative Medicine helped support results. Johnson & Johnson Q3 Earnings Surpass Estimates
• Positive Sentiment: Full-year outlook was raised: J&J now expects 2026 adjusted EPS of approximately $11.05 to $11.15, signaling confidence in its operating momentum despite ongoing portfolio challenges. Johnson & Johnson reports Q3 2026 results
• Positive Sentiment: Dividend maintained: The board declared a quarterly dividend of $1.34 per share, payable December 8, reinforcing J&J’s appeal to income-focused investors. Johnson & Johnson Announces Quarterly Dividend
• Positive Sentiment: New long-term clinical data for TREMFYA showed sustained efficacy in Crohn’s disease, supporting the company’s pharmaceutical pipeline and efforts to offset Stelara-related pressure. TREMFYA Crohn’s disease data
• Neutral Sentiment: J&J is leaning toward spinning off its hips-and-knees business, a move that could sharpen the company’s focus but also creates execution and separation risks. J&J hips-and-knees spinoff
• Negative Sentiment: Reported profitability declined: Third-quarter EPS fell from $2.80 a year earlier, with special charges causing a sharp drop in reported profit despite higher sales. Johnson & Johnson Q3 profit report
• Negative Sentiment: MedTech remains a key concern: Surgery revenue declined, with Middle East conflict disrupting medical-device sales. The weakness raises questions about whether a potential spinoff can resolve the segment’s operational problems. Can a Spinoff Fix Johnson & Johnson’s MedTech Problem?

Insiders Place Their Bets

In related news, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last ninety days. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Down 6.7%

JNJ stock traded down $17.64 on Tuesday, reaching $246.09. 6,065,245 shares of the company traded hands, compared to its average volume of 7,938,428. Johnson & Johnson has a one year low of $184.66 and a one year high of $281.07. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The firm has a fifty day simple moving average of $266.01 and a 200-day simple moving average of $249.31. The company has a market cap of $593.06 billion, a P/E ratio of 28.49, a price-to-earnings-growth ratio of 2.65 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analysts' expectations of $25.38 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm's quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the company posted $2.80 earnings per share. Research analysts anticipate that Johnson & Johnson will post 11.18 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.2%. Johnson & Johnson's payout ratio is currently 62.11%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on JNJ shares. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a report on Monday, August 3rd. Bank of America reaffirmed a "neutral" rating and issued a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday, September 29th. The Goldman Sachs Group restated a "buy" rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a report on Monday, August 3rd. Finally, Royal Bank Of Canada upped their price objective on Johnson & Johnson from $287.00 to $290.00 and gave the stock an "outperform" rating in a report on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $276.22.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.